Women’s health is emerging as one of the most dynamic segments in global healthcare. From fertility tech to menopause platforms, femtech is attracting record investment and could reach a market size of $50–60 billion by 2027 — with Europe producing some of the sector’s most influential companies.
The rise of femtech as a global health industry
Femtech has moved from niche category to major growth sector in less than a decade.
The term covers a wide range of technologies: fertility tracking, menopause care, chronic‑condition management, mental‑health platforms and diagnostic tools designed specifically for women.
The shift is driven by two forces.
First, women’s health has long been underserved by mainstream healthcare systems.
Second, digital health has lowered the barriers to building products that address these gaps.
McKinsey estimates that the global femtech market could reach $50–60 billion by 2027, driven by rising demand for personalised care and better data.
Apps like Flo — one of Europe’s biggest health platforms — show how large the audience can be.
Flo has more than 300 million users and has become a reference point for cycle tracking, fertility insights and reproductive health.
Femtech is no longer a side category.
It is becoming a core part of the digital‑health economy.
Why women’s health is attracting record investment
Investment in women’s health has surged over the past five years.
Venture capital firms are backing femtech for three reasons.
First, the market is huge.
Women make up half the population, yet many health conditions affecting them — from endometriosis to menopause symptoms — have historically received limited research funding.
Second, the technology is improving.
AI‑based cycle prediction, hormone‑tracking wearables and telemedicine platforms have made it easier to deliver personalised care at scale.
Third, demand is rising.
Women are seeking better tools for fertility, pregnancy, postpartum care and long‑term health management.
This demand is global, not regional.
McKinsey notes that investors now see femtech as a structural growth story, not a trend.
Fertility tech, menopause care and chronic conditions
Femtech is not one market.
It is several overlapping markets, each growing quickly.
Fertility tech
Fertility platforms use AI to predict ovulation, analyse hormone patterns and support IVF cycles.
Startups offer at-home testing, teleconsultations and data‑driven treatment plans.
The fertility‑tech segment has seen some of the fastest funding growth in digital health.
Menopause care
The menopause market is going mainstream.
Women in their 40s and 50s are seeking solutions for sleep, mood, hormonal changes and long‑term health risks.
McKinsey highlights menopause as one of the largest untapped opportunities in healthtech.
Chronic conditions and pain
Femtech companies are also targeting conditions like endometriosis, PCOS and chronic pelvic pain — areas where diagnosis is often delayed by years.
AI‑based diagnostic tools and digital‑therapeutic platforms are emerging to fill the gap.
Mental health
Platforms addressing PMS‑related mood changes, postpartum depression and hormonal mental‑health patterns are gaining traction.
These services often use subscription models, making them attractive to investors.
Femtech is expanding because it solves real problems that traditional healthcare has overlooked.
The market outlook: a $50–60 billion sector by 2027
The femtech market is expected to grow rapidly over the next three years.
Several factors support this trajectory:
- rising awareness of women’s health needs
- increased research funding
- normalisation of digital health
- ageing populations
- demand for personalised care
- employer‑sponsored women’s health benefits
Grand View Research and McKinsey both forecast a market size of $50–60 billion by 2027, depending on adoption rates and regulatory environments.
The growth is not limited to consumer apps.
Biotech, diagnostics, medical devices and telemedicine are all expanding under the femtech umbrella.
Europe’s growing role in the femtech ecosystem
Europe is emerging as a major hub for femtech innovation.
The region has produced some of the sector’s most influential platforms, including Flo, Clue, Natural Cycles and a growing number of menopause and fertility‑tech startups.
Europe’s strengths include:
- strong digital‑health regulation
- high adoption of telemedicine
- robust public‑health systems
- growing VC interest in healthtech
- a large, ageing female population
LinkedIn’s analysis of Europe’s healthtech landscape highlights femtech as one of the most promising categories for future unicorns.
While the US remains the largest market, Europe is catching up quickly — especially in fertility tech, menopause care and chronic‑condition management.
The region’s combination of public‑health infrastructure and private innovation gives it a unique advantage.
If current trends continue, Europe could become one of the global centres of femtech development.
Subscribe to EuroLuminant for independent European journalism.
